A new analysis reveals that access to puberty blockers and gender-affirming hormones for transgender youth is limited, with only a minority receiving treatment. The study highlights that among adolescents aged 13 to 17 in the US, the prescription rates for these treatments are low, despite the ongoing political debate surrounding their use. The findings suggest that concerns about over-prescription may be unfounded, as rigorous processes are in place for treatment. Teljes cikk (Euronews.com)